Hollywood, Florida February 1,
2005, STARLIMS Corporation, the leading global provider of
Laboratory Information Management Systems, (LIMS), today unveiled a
joint effort with Lilly MDR-TB partnership in the battle against the
expanding crisis of multi-drug resistant tuberculosis (MDR-TB), a
virulent mutated type of tuberculosis (TB) that is difficult to
treat, and therefore much more likely to spread.
The Lilly MDR-TB Partnership is a
uniquely comprehensive initiative with the World Health Organization
(WHO), the U.S. Department of Health and Human Services' Centers for
Disease Control and Prevention (CDC), Brigham and Women's Hospital (BWH),
an affiliate of Harvard Medical School, the International Council of
Nurses (ICN) and Purdue University to increase the number of trained
personnel and drugs available to treat the expanding crisis of MDR-TB.
Through funding from Lilly,
the CDC have begun the implementation of STARLIMS as a platform for
extensive laboratory–based electronic surveillance of patients
resistance to drugs used for treating MDR-TB, in clinics throughout
Russia and Kazakhstan.
STARLIMS is an enterprise
level information system that brings together all public health
laboratory activities into a single platform, offering comprehensive
reporting, surveillance, and networking capabilities compatible with
national and international standards. Public health solutions from
STARLIMS are designed as a platform for linking between regional
public health partners working under the PHIN framework, HL7
messaging protocols and using LOINC and SNOMED as the common
vocabulary for test names and observations. This functionality
enables cross site sample transfer and data exchange.
The involvement of STARLIMS in Public Health projects and its
contribution to the Eli Lilly MDR-TB partnership is featured on the
World Business Review show hosted by General Alexander Haig, former
Secretary of State, aired February 1, 2005.
“The CDC and STARLIMS
partnership allows us to apply LIMS technology to monitor treatment
effectiveness. This is a very critical component of our whole
effort to address MDR-TB”, stated. “Dr. Gail Cassell, vice
president, scientific affairs and distinguished research scholar for
infectious diseases, Eli Lilly and Company.
“STARLIMS was honored to be
asked to join the CDC in the Lilly MDR-TB partnership that addresses
one of today’s most challenging public health threats” said Isaac
Friedman, president & CEO of STARLIMS Corporation. “Our specific
role is to provide STARLIMS licenses and know-how necessary to
implement an effective MDR-TB monitoring and surveillance
infrastructure throughout a network of WHO sponsored treatment
centers”.
About Lilly MDR-TB
Partnership
The Lilly MDR-TB
partnership is a pioneering initiative led by Eli Lilly and Company
that will increase the number of trained medical personnel and drugs
available to treat people with multi-drug resistant tuberculosis, an
expanding global health crisis. Described as a new paradigm for
addressing global public health threats, the Lilly MDR-TB
Partnership is an example of Lilly’s ongoing commitment to provide
“Answers That Matter.” Additional information about Lilly MDR-TB
Partnership is available at
STARLIMS Corporation
delivers cost effective, easy-to-use collaborative LIMS solutions to
organizations in the public health, pharmaceutical, petrochemical,
forensics, food & beverage, environmental and chemical industries.
Full featured and highly flexible our multilingual laboratory
information management system provides complete traceability leading
to regulatory compliance, without compromising process versatility.
A 15 year track record has earned us
recognition for “future proofing” our customers’ investments and
serving as a platform for new implementations and straightforward
conversions of legacy systems. To learn more about STARLIMS please
visit us at
www.starlims.com
